Congress Program

Monday, 30 October

07:30	Registration
08:30	Session I: Opening
	Welcome to London Distinguished Speaker, to be announced. Importance of Disease Prevention to the UK and World (invited) Introduced by Julia Manning, Founding Director, 2020health, UK (Co-Chair) Importance of Disease Prevention to the UK and World “Metabesity—What, Why and How” Alexander Fleming, Executive Chairman and Founder, Kinexum, USA (Co-Chair) “It’s as much about Economics as Science” Joseph C. Cook, Jr., Executive Chairman of the Board & President, NuSirt Biopharma, USA Overview of the Conference Lawrence Steinman, George A. Zimmermann Professor and Professor of Pediatrics, Stanford University, USA (Co-Chair)
	Session II: Overviews of Metabesity Targets
	Aging, From Hope to Promise in Targeting Aging Steven Austad, University of Alabama, Birmingham, USA Diabetes Neurodegeneration Sir John Bell, Regius Professor of Medicine, Oxford University, UK Cancer Ashok Venkitaraman, Ursula Zoellner Professor of Cancer Research,University of Cambridge, and Director of the Medical Research Council (MRC) Cancer Unit, UK
10:30	Coffee Break, Poster Viewing and Visit the Exhibition
11:00	Session III: Metabesity-Related Basic Science
	NAD Metabolism and Aging Eric Verdin, Buck Institute for Research on Aging, California, USA Glucose Metabolism as a Modulator of Aß Toxicity Teresa Niccoli, University College London, UK Targeting Metabolic Pathways and Delaying Aging in Rodents Randy Strong, UT Health Center, San Antonio, USA
12:30	Lunch Break, Poster Viewing and Visit the Exhibition
13:30	Session IV: Tools for Approaching Metabesity
	Nutritional Biochemistry and Aging Vitamin D and Obesity Jenny Gunton, Chair of Medicine, University of Sydney, Westmead Hospital, Australia Neuroinflammation - Using Big Data to Inform Clinical Practice Lars Fugger, Weatherall Institute of Molecular Medicine, Oxford, UK Interactions between Genetic, Lifestyle/Environmental Risk Factors for Multiple Sclerosis Tomas Olsson, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
15:00	Coffee Break, Poster Viewing and Visit the Exhibition
15:30	Session V: Metabesity Interventions under Development
	Clinical Studies of mTORC1 Compounds Diabetes Prevention, What have we Learned from DPT et al? Itamar Raz, Hadassah Medical School at the Hebrew University of Jerusalem, Israel Qualifying Clinical Candidates for Anti-Aging Interventions Nir Barzilai, Albert Einstein College of Medicine, NY, USA Hepatic Steatosis, What do NASH trials teach us? Brian Harvey, Executive Vice President, Scientific and Regulatory Affairs at the non-profit Global Liver Institute, USA Targeting Aging with Metformin - Proof of Concept Steve Kritchevsky, Wake Forest Baptist Medical Center, Winston-Salem, USA
17:30	End of Day One

Tuesday, 31 October

07:30	Registration
08:30	Session VI: Tall Orders for Evidence — Clinical, Regulatory, Ethical, Economic
	Clinical Evidence Aimed at the Regulators Philip Home, Professor of Diabetes Medicine, Newcastle University, UK Regulatory Perspectives (invited) “What Evidence Do Payers Need and What Can We Pay? Gillian Leng, Deputy Chief Executive, National Institute for Health and Care Excellence, UK Barry Straube, National Healthcare Policy, Quality, Clinical/Academic Expert, USA Ethics for an Age of “Metabesity”? Joshua Hordern, Associate Professor of Christian Ethics, Faculty of Theology and Religion, University of Oxford, UK Voice of the Would Be Non-Patient Julia Manning, Founding Director, 2020health, UK (Co-Chair)
10:30	Coffee Break, Poster Viewing and Visit the Exhibition
	Session VII: Solutions
	a. It’s a Drug Big Pharma can/should do this (invited) b. It’s a Nutritional The Science is there (invited) Addressing sarcopenia today and tomorrow c. It’s an App We are on it Stephanie Tilenius, Co-Founder and CEO, Vida Health, USA d. It’s Something Else Lucy Rose, Lucy Rose & Associates, USA
12:30	Lunch Break, Poster Viewing and Visit the Exhibition
13:30	Session VII: Solutions (continued)
	e. Financing (Capital Markets, Philanthropy, Public Funding) Roundtable f. Commercialization Roundtable Joseph C. Cook, Jr., Executive Chairman of the Board & President, NuSirt Biopharma, USA
15:00	Coffee Break, Poster Viewing and Visit the Exhibition
15:30	Session VIII: Where Do We Go From Here
	Panel and Round Table Discussion Moderators: Julia Manning, Founding Director, 2020health, UK (Co-Chair) Thomas Seoh, President and Chief Executive Officer, Kinexum, USA a. What are some priority scientific shots? b. Is there a clinical trial template for Metabesity agents? c. Can regulators offer some pathways? d. Will payers pay? e. Will the people come?
16:30	End of Congress